Big Pharma Split Corp Class A (PRM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Big Pharma Split Corp Class A (PRM) has a cash flow conversion efficiency ratio of -0.050x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-910.98K ≈ $-658.99K USD) by net assets (CA$18.27 Million ≈ $13.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Big Pharma Split Corp Class A market capitalisation for the company's overall valuation and market capitalisation.
Big Pharma Split Corp Class A - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Big Pharma Split Corp Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Big Pharma Split Corp Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Big Pharma Split Corp Class A ranked by their cash flow conversion efficiency. Explore PRM cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nepa AB
ST:NEPA
|
-0.412x |
|
DeepMarkit Corp.
NASDAQ:MKTSF
|
0.168x |
|
e-future.Co.Ltd
KQ:134060
|
0.012x |
|
Argenica Therapeutics Ltd
AU:AGN
|
-1.602x |
|
Neungyule Education Inc
KQ:053290
|
0.065x |
|
CMX GOLD+SILVER CORP.
F:6GS
|
-4.784x |
|
FIPP S.A.
PA:FIPP
|
0.002x |
|
Intersport Polska S.A.
WAR:IPO
|
0.401x |
Annual Cash Flow Conversion Efficiency for Big Pharma Split Corp Class A (2017–2025)
The table below shows the annual cash flow conversion efficiency of Big Pharma Split Corp Class A from 2017 to 2025. View latest Big Pharma Split Corp Class A stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$18.27 Million ≈ $13.21 Million |
CA$-1.06 Million ≈ $-763.18K |
-0.058x | +39.01% |
| 2024-12-31 | CA$13.68 Million ≈ $9.90 Million |
CA$-1.30 Million ≈ $-937.16K |
-0.095x | -112.66% |
| 2023-12-31 | CA$15.85 Million ≈ $11.47 Million |
CA$11.86 Million ≈ $8.58 Million |
0.748x | +1208.10% |
| 2022-12-31 | CA$19.73 Million ≈ $14.27 Million |
CA$1.13 Million ≈ $816.29K |
0.057x | +114.24% |
| 2021-12-31 | CA$22.40 Million ≈ $16.21 Million |
CA$-9.00 Million ≈ $-6.51 Million |
-0.402x | -221.81% |
| 2020-12-31 | CA$13.19 Million ≈ $9.54 Million |
CA$4.35 Million ≈ $3.15 Million |
0.330x | -38.03% |
| 2019-12-31 | CA$16.31 Million ≈ $11.80 Million |
CA$8.68 Million ≈ $6.28 Million |
0.532x | +689.14% |
| 2018-12-31 | CA$18.84 Million ≈ $13.63 Million |
CA$1.27 Million ≈ $919.19K |
0.067x | +104.07% |
| 2017-12-31 | CA$18.68 Million ≈ $13.51 Million |
CA$-30.95 Million ≈ $-22.39 Million |
-1.657x | -- |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.